NCT04854928 - Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

May 31, 2022

Conditions

COVID-19

Interventions

DRUG

LTX-109 gel, 3%

A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

DRUG

Placebo gel

A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Trial Locations (1)

SE-752 37

RECRUITING

ClinSmart Sweden AB, Uppsala